Clincosm LogoSign in Get a demo

Evaluating Performance and Safety of the Medical Device Jalucomplex in the Treatment of Facial and Neck Tissue Defects

Sponsor
I.R.A. Istituto Ricerche Applicate S.p.A. (Other)
Overall Status
Recruiting
CT.gov ID
NCT05239351
Collaborator
Opera CRO, a TIGERMED Group Company (Other)
48
Enrollment
1
Location
3
Arms
4.5
Anticipated Duration (Months)
10.7
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The Research Question of the present study is the following: in a population of men and women presenting facial and neck dermal tissue defects (scars, hypertrophic scars, depressed plaques, and lipodystrophy defects) will linear hyaluronic acid (Jalucomplex®) significantly decrease and / or improve their appearance, results observed after 4 and 8 weeks?

Condition or Disease Intervention/Treatment Phase
  • Device: Jalucomplex
 N/A

Detailed Description

Jalucomplex® action is to increase the volume of dermal-epidermal tissue, based on the natural ability of hydrophilic hyaluronic acid molecules to bind to an amount of water many times greater than their weight. This allows to fill the intradermal spaces and integrate the intercellular matrix, conferring turgidity to the tissues. Linear hyaluronic acid is a polymer that represents one of the essential components of human skin, subcutaneous and connective tissue; its ability to form complexes with water molecules increases the level of tissue hydration, turgidity and plasticity. These characteristics allow Jalucomplex® to be used as a temporary filler for subcutaneous areas to correct small defects in the dermal tissue due to lipodystrophies or the presence of fibrotic tissues as scars, caused by pathologies or trauma. Non-crosslinked hyaluronic acid generates a lower reactivity that crosslinked forms, biocompatibility of hyaluronic acid-based materials decreasing with an increase in the number of modifications to this polysaccharide

Study Design

Study Type:
Interventional
Anticipated Enrollment :
48 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
This is a multi-center, open-label, non-randomized clinical investigationThis is a multi-center, open-label, non-randomized clinical investigation
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Open, Non-comparative, Multicentre Clinical Investigation to Evaluate the Performance and Safety of the Medical Device Jalucomplex® (Hyaluronic Acid-dermal Filler) in the Treatment of Facial and Neck Dermal Tissue Defects
Actual Study Start Date :
Mar 7, 2022
Anticipated Primary Completion Date :
Jun 11, 2022
Anticipated Study Completion Date :
Jul 22, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Jalucomplex 1

Sixteen patients will be administered Jalucomplex® 1 for the treatment of minor-sized facial and neck dermal tissue defects (scars, hypertrophic scars, depressed plaques, and lipodystrophy defects)

Device: Jalucomplex
Device: Jalucomplex Jalucomplex is an injectable intradermal gel containing sodium salts derived from hyaluronic acid.
Experimental: Jalucomplex 2

Sixteen patients will be administered Jalucomplex® 2 for the treatment of medium-sized facial and neck dermal tissue defects (scars, hypertrophic scars, depressed plaques, and lipodystrophy defects)

Device: Jalucomplex
Device: Jalucomplex Jalucomplex is an injectable intradermal gel containing sodium salts derived from hyaluronic acid.
Experimental: Jalucomplex 3

Sixteen patients will be administered Jalucomplex® 3 for the treatment of major-sized facial and neck dermal tissue defects (scars, hypertrophic scars, depressed plaques, and lipodystrophy defects)

Device: Jalucomplex
Device: Jalucomplex Jalucomplex is an injectable intradermal gel containing sodium salts derived from hyaluronic acid.

Outcome Measures

Primary Outcome Measures

  1. POSAS score assessed by Investigator and patient [8 weeks]

    To evaluate the overall performance of the medical dermal filler Jalucomplex® in treating facial and neck dermal tissue defects (scars, hypertrophic scars, depressed plaques, and lipodystrophy defects) in terms of change in Patient and Observer Scar Assessment Scale (POSAS) score, assessed by Investigators and patients at 8 weeks (56 days) after the initiation of treatment, compared to Visit 1 (day 0).

  2. POSAS score assessed by Investigator and patient [4 weeks]

    To evaluate the overall performance of the medical dermal filler Jalucomplex® in treating facial and neck dermal tissue defects (scars, hypertrophic scars, depressed plaques, and lipodystrophy defects) in terms of change in Patient and Observer Scar Assessment Scale (POSAS) score, assessed by Investigators and patients at 4 (28 days) after the initiation of treatment, compared to Visit 1 (day 0).

  3. Investigator Global Assessment of Performance (IGAP) [8 weeks]

    To evaluate the global performance of product assessed by Investigator through photos taken at each visit (IGAP), at week 8 (day 56), compared to Visit 1 (day 0)

  4. Adverse event incidence [8 weeks]

    To evaluate the safety of the device trough Adverse event incidence assessed by Investigators at all visits and reported according to the current legislation

  5. Serious adverse event incidence [8 weeks]

    To evaluate the safety of the device trough Serious Adverse Event incidence assessed by Investigators at all visits and reported according to the current legislation

  6. Adverse device event incidence [8 weeks]

    To evaluate the safety of the device trough adverse device event incidence assessed by Investigators at all visits and reported according to the current legislation

  7. Serious adverse device event incidence [8 weeks]

    To evaluate the safety of the device trough Serious adverse device event incidence assessed by Investigators at all visits and reported according to the current legislation

Secondary Outcome Measures

  1. Global Aesthetic Improvement Scale evaluated by the patient (GAIS) [8 weeks]

    To evaluate general appearance after treatment assessed by the patient at 4 and 8 weeks (28 and 56 days) using the Global Aesthetic Improvement Scale (GAIS). The scale evaluates the appearance from 1 (very much improved) to 5 (worse than original condition) .

  2. Treatment satisfaction assessment by the patient [8 weeks]

    To assess the patient satisfaction 4 and 8 weeks (28 and 56 days), providing their degree of satisfaction with the treatment on a four-point scale (very satisfied, satisfied, moderately satisfied, or not satisfied)

  3. Investigator Global Assessment of Safety (IGAS) [8 weeks]

    To evaluate the global safety of product assessed by Investigator (IGAS), at week 8 (day 56), compared to Visit 1 (day 0), providing the safety on a four point scale from 4 meaning poor safety to 1 meaning very good safety.

  4. Patient Global Assessment of Safety (PGAS). [8 weeks]

    To evaluate the global safety of product assessed by the patient ( PGAS), at week 8 (day 56), compared to Visit 1 (day 0), providing the safety on a four point scale from 4 meaning poor safety to 1 meaning very good safety.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  1. Men or women with age ≥ 18 and ≤ 65 years.

  2. Patients with facial and neck dermal tissue defects (scars, hypertrophic scars, depressed plaques, and lipodystrophy defects), caused both by pathologies or trauma, seeking tissue augmentation treatment and willing to receive HA Filler.

  3. Patients who agree to discontinue any other dermatological treatment and procedures during the study.

  4. Patients willing to provide signed informed consent to clinical investigation participation.

  5. Patients able to communicate adequately with the Investigator and to comply with the requirements for the entire study.

Exclusion Criteria:

  1. Past or current bleeding disorders.

  2. Use of aspirin and antiplatelet agents a week prior to treatment.

  3. Prior or planned use of topical injection to the face and the neck (steroid, retinoid: applicable only to drugs, not applicable to cosmetics), within 4 weeks prior to screening or during this study (steroid ointment for therapeutic objectives is allowed for short -term use of ≤14 consecutive days.).

  4. Use of immunosuppressive, chemotherapies, or systemic corticosteroids within 12 weeks from screening.

  5. History of anaphylaxis or severe complicated allergy symptoms.

  6. Clinically significant cardiovascular, digestive, respiratory, endocrine, or central nervous system disorders or previous mental disorders that may significantly affect the study.

  7. Known hypersensitivity skin reaction to hyaluronic acid or hypersensitivity skin reaction to the investigational device based on intradermal test results at visit 1.

  8. Evidence or history of autoimmune disease or compromised immune system.

  9. Treatment with anticoagulants, thrombolytics, or platelet inhibitors within 1 week prior to study participation.

  10. Prior permanent fillers or fat graft procedures around facial and neck dermal tissue defects.

  11. Facial and neck dermal tissue defects correction procedures (e.g., botulinum toxin A injection, face lift, soft tissue augmentation, medium-depth peel, dermal photo-rejuvenation, etc.) around infraorbital region within 6 months prior to study participation.

  12. History of hypersensitivity to local anaesthetic of amide type or HA.

  13. History of keloid formation on the face and the neck.

  14. Evidence of active infection on the face and the neck.

  15. Wound, skin disorder or infection around facial and neck dermal tissue that may affect the efficacy assessment.

  16. Pregnant woman, lactating woman, and man or woman of childbearing potential who is planning a pregnancy or is unwilling to use appropriate methods of contraception* during the study. *Methods of contraception: hormonal contraceptive, intrauterine device or intrauterine system, double barrier method (condom with spermicide/diaphragm or cervical cap with spermicide), surgical sterilization (vasectomy, tubal ligation, etc.).

  17. Need to exposure to the sun, UV rays and extreme conditions of heat for at least a week after the treatment.

  18. Need to have direct or indirect contact with quaternary ammonium salts during the study.

  19. As with all dermal filler procedures, the product should not be used in vascular rich areas. Using the product at sites such as Glabella and nose may inadvertently be injected into the blood vessels, resulting in symptom of vessel occlusion such as colour vision deficiency and blindness.

  20. Patients with illness, or other medical condition that, in the opinion of the investigator, would compromise participation or be likely to lead to hospitalization during the study.

  21. Participation in an interventional clinical study or administration of any investigational agents in the previous 30 days.

Contacts and Locations

Locations

Site City State Country Postal Code
1 SCM Dr. Rosu Timişoara Timis Romania 300425

Sponsors and Collaborators

  • I.R.A. Istituto Ricerche Applicate S.p.A.
  • Opera CRO, a TIGERMED Group Company

Investigators

  • Principal Investigator: Mihaela Fratila, SCM Dr. Rosu

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
I.R.A. Istituto Ricerche Applicate S.p.A.
ClinicalTrials.gov Identifier:
NCT05239351
Other Study ID Numbers:
  • OPIRA/0321/MD
First Posted:
Feb 14, 2022
Last Update Posted:
Mar 31, 2022
Last Verified:
Mar 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Lipodystrophy
Cicatrix

Study Results

No Results Posted as of Mar 31, 2022